Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe

Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe

Abstract Background Renal cell carcinoma (RCC) was historically considered to be less responsive to radiation therapy (RT) compared to other cancer indications. However, advancements in precision high-dose radiation delivery through single-fraction and multi-fraction stereotactic ablative radiothera...

Full description

Bibliographic Details
Main Authors: Hari K. Rachamala, Vijay S. Madamsetty, Ramcharan S. Angom, Naga M. Nakka, Shamit Kumar Dutta, Enfeng Wang, Debabrata Mukhopadhyay, Krishnendu Pal
Format: Article
Language:English
Published: BMC 2024-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Renal cancer
Radiation therapy
mTOR
Survivin
Mitotic catastrophe
Online Access:https://doi.org/10.1186/s13046-024-03079-8

Internet

https://doi.org/10.1186/s13046-024-03079-8

Similar Items